Evolving Considerations in the Treatment and Management of Amyotrophic Lateral Sclerosis (ALS): Optimizing Strategies for Slowing Disease Progression

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Mitsubishi Tanabe Pharma America.

Description:
Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s disease, is a progressive
neurodegenerative disease that affects nerve cells in the brain and the spinal cord. An estimated 20,000 people in the United States are living with ALS. It is a progressive disease in which the motor neurons eventually die. Mortality is usually the result of respiratory failure. Although most patients with ALS die within 3 to 5 years after symptoms first appear, about 20% of patients with ALS will live 5 years, 10% will live 10 years, and about 5% will live 20 years or more. Currently, there is no cure for ALS. Fortunately for patients with ALS, the treatment paradigm has expanded in recent years, giving medical directors and clinicians many more options in managing symptoms and delaying progression in the ALS patient population. This activity will feature strategies to overcome challenges in the optimal treatment of ALS and highlight the role of managed care professionals in making informed decisions on therapies that will improve quality of life, slow the disease progression, and minimize costs.

Upon completion of this activity, participants will be able to:

  • Examine the impact, direct and indirect costs, and unmet needs of amyotrophic lateral sclerosis (ALS) and the value of early diagnosis.

  • Analyze the underlying pathophysiology of ALS and the barriers to accurate and early diagnosis.

  • Discuss the mechanisms of action, efficacy and safety of disease-modifying and symptomatic pharmacotherapies for patients with ALS.

  • Explore recent real-world and clinical data for currently available and investigational agents, including options that slow disease progression, for the management of ALS.

  • Apply recent data and scientific advances to drug utilization management strategies.

  • Identify methods to navigate access to appropriate ALS therapies and discuss managed care considerations around those therapies.

     

Faculty: Hiroshi Mitsumoto, MD, DSc
Wesley J Howe Professor of Neurology, Eleanor and Lou Gehrig ALS Center
Department of Neurology, Columbia University Medical Center

Disclosure:

Dr. Mitsumoto serves on an advisory board for Amylyx. He has served on the speaker's bureau for PTC Bio. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Mitsubishi Tanabe Pharma America.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue